Replicel gave its presentation today at the Stem Cell on the Mesa Conference.  Although my regular day job meant that I missed the live webcast, Replicel kindly Tweeted its presentation summary to me.

I was expecting the presentation to be dominated by the company’s achilles tendinosis related work, but there was a good amount of information on the male pattern baldness work (RCH-01) too.  As previously discussed on this blog, their phase 2 trials began in Germany in 2014.  However, it seems like the Japanese trials have been delayed and moved from late 2014 to the first half of 2015. Both trials will last for 1 year.

They also presented their completed 6-month phase 1 trial results. Average density across all participants increased 11.8 percent with no side effects.  I wonder if this average density increase figure will go up significantly as they increase dosage and time frame?  I would hope so.

FYI — today and tomorrow, you can listen to some excellent track 1 webcasts and track 2 webcasts from the Mesa Conference.  The future can’t come fast enough.